StagePIPE | IPO
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. To protect this pipeline, aTyr built an intellectual property estate comprising 24 patents and over 200 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation, for which there are currently limited or no treatment options.
Compete with aTyr Pharma?
Ensure that your company and products are accurately represented on our platform.
aTyr Pharma's Products & Differentiators
Efzofitimod is a first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2)
Expert Collections containing aTyr Pharma
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
aTyr Pharma is included in 1 Expert Collection, including Biopharma Tech.
aTyr Pharma Patents
aTyr Pharma has filed 116 patents.
The 3 most popular patent topics include:
- Molecular biology
- Protein domains
- Clusters of differentiation
Immunology, Clusters of differentiation, Psychotherapy, Drug discovery, Protein domains
Immunology, Clusters of differentiation, Psychotherapy, Drug discovery, Protein domains
Latest aTyr Pharma News
May 22, 2023
Location: Ballroom C (Level 3), Walter E. Washington Convention Center The poster presents findings that investigate the modulatory functions of efzofitimod on monocytes by evaluating peripheral blood mononuclear cells from pulmonary sarcoidosis patients or healthy donors for surface marker expression by flow cytometry and cytokine/chemokine secretion by immunoassay. Neuropilin-2, the binding partner for efzofitimod, is expressed on circulating monocytes and macrophages in lung granulomas from pulmonary sarcoidosis patients and exhibits a more inflammatory phenotype compared to healthy donors. Efzofitimod modulates immune responses in myeloid cells by downregulating pro-inflammatory cytokines and receptors that are dysregulated in sarcoidosis, including TNFa, IL-6, MIP-1a and MCP-1. These findings enhance our understanding of efzofitimod’s mechanism of action and demonstrate the way in which it modulates inflammatory responses in pulmonary sarcoidosis patients. Location: Area F, Hall C (Lower Level), Walter E. Washington Convention Center The poster presents findings from a population pharmacokinetic model and exposure-efficacy analyses using data from a Phase 1 study of efzofitimod in healthy volunteers and Phase 1b/2a study in patients with pulmonary sarcoidosis. Analyses assessed the relationship between efzofitimod exposure and three prespecified efficacy parameters and showed that administration of efzofitimod led to an exposure-dependent decrease in the extent of oral corticosteroid usage, increase in lung function as measured by percent predicted forced vital capacity and improvement in clinical symptoms as measured by the King’s Sarcoidosis Questionnaire-Lung score. These findings of a positive exposure-efficacy analysis across multiple clinically relevant endpoints support proof-of-concept and efficacy in pulmonary sarcoidosis. The company is also hosting an Industry Theater presentation. Details appear below. Title: Efzofitimod: An Emerging Treatment for Sarcoidosis? Session Format: Industry Theater Presentation Speaker: Daniel A. Culver, D.O, Chair of Pulmonary Medicine, Cleveland Clinic Date and Time: Tuesday, May 23, 2023, at 1:30 p.m. Location: Exhibit Hall A-B, Booth #102, Walter E. Washington Convention Center Dr. Culver will discuss efzofitimod as an emerging treatment for sarcoidosis, including its novel mechanism as a way to resolve inflammation and prevent the progression of fibrosis in patients with pulmonary sarcoidosis and the Phase 3 EFZO-FIT™ study, which is currently enrolling patients with pulmonary sarcoidosis. About Efzofitimod aTyr is developing efzofitimod as a potential therapeutic for patients with fibrotic lung disease. Efzofitimod, a fusion protein comprised of the immunomodulatory domain of histidyl-tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates innate and adaptive immune response in inflammatory disease states. aTyr’s lead indication for efzofitimod is pulmonary sarcoidosis, a major form of interstitial lung disease. Clinical proof-of-concept for efzofitimod was recently established in a Phase 1b/2a multiple-ascending dose, placebo-controlled study of efzofitimod in patients with pulmonary sarcoidosis, which demonstrated safety and a consistent dose response and trends of benefit of efzofitimod compared to placebo on key efficacy endpoints, including steroid reduction, lung function, clinical symptoms and inflammatory biomarkers. aTyr is currently conducting EFZO-FIT™, a global pivotal Phase 3 study of efzofitimod in pulmonary sarcoidosis. About aTyr aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit http://www.atyrpharma.com . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “believes,” “expects,” “intends,” “may,” “plans,” “forward,” “potential,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include, among others, statements regarding the potential of efzofitimod to be a transformative, disease modifying therapy for ILD, and the potential applications of efzofitimod. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding geopolitical and macroeconomic events, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and in our subsequent SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contact:
aTyr Pharma Frequently Asked Questions (FAQ)
When was aTyr Pharma founded?
aTyr Pharma was founded in 2005.
Where is aTyr Pharma's headquarters?
aTyr Pharma's headquarters is located at 3545 John Hopkins Court, San Diego.
What is aTyr Pharma's latest funding round?
aTyr Pharma's latest funding round is PIPE.
How much did aTyr Pharma raise?
aTyr Pharma raised a total of $180.5M.
Who are the investors of aTyr Pharma?
Investors of aTyr Pharma include EcoR1 Capital, Sphera Funds, Deerfield Management, T. Rowe Price, Federated Investors and 10 more.
Who are aTyr Pharma's competitors?
Competitors of aTyr Pharma include Humanetics, Arena Pharmaceuticals, Eyegate Pharmaceuticals, Santaris Pharma, MacroGenics and 16 more.
What products does aTyr Pharma offer?
aTyr Pharma's products include Efzofitimod.
Compare aTyr Pharma to Competitors
Neurocure is a specialty pharma company working on psychiatric and central nervous system diseases.
LaborMed Pharma, aims to offer modern and accessible treatments for cardiovascular diseases, those affecting the central nervous system, the metabolism a.s.o., medicines produced in a state-of-the-art factory in Bucharest.
Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.
Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.